Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment ...

Danish biopharma powerhouse Novo Nordisk is taking another bold move in the obesity market, this time licensing a new type of GLP-1 that could directly compete with a candidate in Eli Lilly’s ...

For Novo Nordisk A/S investors (NVO), things couldn't have gotten to a worse start this week. Just when the market was preparing for a bottom, as NVO has been consolidating constructively over the ...